Status:
UNKNOWN
The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
Lead Sponsor:
MTI University
Collaborating Sponsors:
National Institute of Diabetes and Endocrinology, Egypt
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
40-60 years
Brief Summary
The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and cardiovascular protection in Type 2 Diabetic Patients
Detailed Description
This study aims to investigate the effect of daily oral DPP4 inhibitors and oral metformin on neurodegeneration in type 2 diabetic patients. This study aims to compare between the cardiovascular prot...
Eligibility Criteria
Inclusion
- Patient should be diagnosed with Type 2 diabetes mellitus (T2DM) and guided with HA1c ≥7, age ≥40 years.
- moderate hypertension.
Exclusion
- • Diabetic patients who have been currently receiving anti-diabetic agents other than metformin and/or insulin
- Patients with type 1 DM, active liver disease, recent history of cardiovascular disease (acute coronary syndrome, coronary artery intervention, New York Heart Association Class III/IV heart failure, stroke, transient ischemic neurologic event, or new/worsening symptoms of coronary heart disease or cerebrovascular disease), severe peripheral vascular disease, triglyceride levels ≥ 600 mg/dL, history of HIV infection, pancreatitis, malignancy or clinically important hematologic disorder, and an estimated glomerular filtration rate (eGFR; calculated using the Modification of Diet in Renal Disease formula) less than 30 mL/min/1.73 m2.
- Moreover, patients with dementia, AD, those were in delirium status during evaluation period, patients with psychotic disease (schizoaffective disorder, etc.)
- Alcohol and substance addiction were not enrolled in the study.
- Also, patients who have any hypersensitivity to metformin or to DPP4 inhibitors were also excluded.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05429554
Start Date
June 1 2022
End Date
September 1 2022
Last Update
June 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of diabetes and endocrinology
Cairo, Al Kasr Al Aini, Egypt